Ablynx today announced the appointment of Robert Friesen, PhD, as Chief Scientific Officer (CSO), effective 1 March 2018.
Dr Friesen will lead the Company’s scientific, research and technology activities and become a member of the Executive Committee. He succeeds Dr Antonin de Fougerolles, Ablynx’s previous CSO, who left the Company last year to become Chief Executive Officer (CEO) at Evox Therapeutics.
Dr Friesen has more than 20 years of experience in the biopharmaceutical industry, leading multiple Research and Development (R&D) organisations. Dr Friesen joins Ablynx from ProQR Therapeutics, a clinical stage biotechnology company, where he is currently Senior Vice President, heading the Science and Early Development division. Prior to joining ProQR Therapeutics, Dr Friesen worked at Janssen BioTherapeutics, a Johnson & Johnson Company as Global Head of Biologics Research, where he established an efficient R&D organisation of more than 200 scientists and professionals located in Europe and US; and at the Crucell Vaccine Institute, a Johnson & Johnson Company, as Vice President Preclinical and Clinical Research where he led the team responsible for discovery, production and preclinical development of monoclonal antibodies. Before Crucell Vaccine Institute, he was Head of Preclinical & Early Clinical Development at MorphoSys.
Dr Friesen holds a PhD in biochemistry from the University of Texas and performed postdoctoral research at the University of Groningen.
Welcoming Dr Friesen to the team, Dr Edwin Moses, CEO of Ablynx, said:
“Robert brings an extensive track record of successfully initiating and executing new drug discovery programmes as well as building strong research organisations. We are pleased to have him join our team and lead our company’s research activities at such an important and exciting time for Ablynx. We will be able to leverage his critical expertise and proven leadership capabilities as we expand our proprietary Nanobody product pipeline and execute on our multiple strategic collaborations with major pharmaceutical companies. We look forward to welcoming Robert as we continue to advance our leading Nanobody platform to deliver meaningful products to patients around the world, and create substantial value for Ablynx’s shareholders.”
Commenting on his appointment, Dr Friesen added:
“I have long admired Ablynx and am excited to join the Company at such an important time. With Ablynx’s upside potential, I look forward to meaningfully contributing to Ablynx’s momentum and advancing our leading Nanobody platform to help drive forward the Company’s strategy of becoming a fully integrated biopharmaceutical company. With Ablynx’s strong pipeline, platform and technology, I am confident that our talented team will continue to deliver novel products to patients that address unmet medical needs where there are currently limited or no therapeutic options.”
With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.
Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.
Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.